# Neogen Chemicals share price today (Neogen Chemicals Ltd, NSE: NEOGEN)

> Neogen Chemicals share price today: ₹2,180.00 at the NSE close on 3 November 2026, up 51.1% in a year. Neogen Chemicals (NSE: NEOGEN) is worth ₹6,550 crore, trades at a P/E of 161.7 and has closed between ₹1,054.70 and ₹2,488.40 over the past 52 weeks. > Neogen Chemicals Ltd's share price has risen faster than its earnings: +51.1% in a year, against −17.4% for earnings per share. NEOGEN · Speciality Chemicals · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/neogen-chemicals-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Getting better, from the last 12 quarters
- Price: ₹2,180.00 (+51.1% in a year)
- P/E: 161.7× (higher than 92% of the last 7.5 years)
- Revenue (Sep 2026): ₹296 Cr (+41.8% on a year ago)
- Profit (Sep 2026): ₹8.2 Cr (+144.2% on a year ago)
- Operating margin: 15.3% (+1.0 points on a year ago)
- ROCE: 6%, FY26
- ROIC: 4.0%, against a 12.0% cost of capital: −8.0 points

The main question: profits are rising, but only −64% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Neogen Chemicals share price today? Neogen Chemicals Ltd's share price was ₹2,180.00 at the close on 3 November 2026. It has been rising for 26 weeks. That is 11.7% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹1,055 and ₹2,488, and at that close it sat 78% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 14 weeks in a row. Over the last 7.5 years the share price moved +732% while the NIFTY 500 moved +139%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Neogen Chemicals this quarter? 7 points in one quarter and highest quarterly revenue in 16 quarters. 1. Revenue up on a year earlier for 10 quarters in a row In the September 2026 quarter revenue was ₹296 crore, +41.8% on a year earlier. 2. Promoters cut their stake by 4.7 points in one quarter From 53% to 48.3% in the September 2026 quarter. 3. Highest quarterly revenue in 16 quarters Revenue of ₹296 crore in the September 2026 quarter is the highest of the last 16 quarters. ## What are Neogen Chemicals' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Neogen Chemicals reported revenue of ₹296 crore, up 41.8% from ₹209 crore a year earlier, and a profit of ₹8.23 crore, up 144.2% from ₹3.37 crore. ### Neogen Chemicals results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹296 crore | ₹209 crore | +41.8% |
| Profit | ₹8.23 crore | ₹3.37 crore | +144.2% |
| Earnings per share | ₹2.74 | ₹1.28 | +114.1% |
| Operating margin | 15.3% | 14.4% | +1.0 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). The newest call in our records is from 28 September 2026, about April to June 2026; a call about these results is not in our records yet. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Neogen Chemicals share price history? Neogen Chemicals closed at ₹2,180.00 on 3 November 2026, up 51.1% from ₹1,442.60 a year earlier (31 October 2025) and up 73.3% over five years. Its highest weekly close since May 2019 was ₹2,488.40 on 18 September 2026. ### Neogen Chemicals share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹2,173.70 | +0.3% |
| 1 month ago · 1 Oct 2026 | ₹2,407.10 | −9.4% |
| 6 months ago · 30 Apr 2026 | ₹1,637.50 | +33.1% |
| 1 year ago · 31 Oct 2025 | ₹1,442.60 | +51.1% |
| 3 years ago · 3 Nov 2023 | ₹1,552.50 | +40.4% |
| 5 years ago · 4 Nov 2021 | ₹1,257.90 | +73.3% |
| Earliest weekly close in our records · 10 May 2019 | ₹262.05 | +731.9% |
| Highest weekly close since May 2019, also the 52-week high · 18 Sep 2026 | ₹2,488.40 | −12.4% |
| Lowest weekly close since May 2019 · 17 May 2019 | ₹249.70 | +773.0% |
| 52-week low (weekly close) · 5 Dec 2025 | ₹1,054.70 | +106.7% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (399 weekly closes from 10 May 2019 to 3 November 2026.)

## What is the latest news on Neogen Chemicals? 3 Nov 2026: Neogen Chemicals closed at ₹2,180.00, up 0.3% on the week and down 9.4% on the month. Results for July to September 2026: Revenue up 41.8% and profit up 144.2% on a year earlier. ### Earlier

- 28 Sep 2026: Neogen Chemicals held its results call for April to June 2026. Management guided: Base-company revenue ₹1,050 crore this year. - 13 Aug 2026: ex-date for a dividend of ₹1 a share. ## What dividend does Neogen Chemicals pay? Neogen Chemicals paid ₹1 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.05% at the ₹2,180.00 close on 3 November 2026. The last was a dividend of ₹1 a share, ex-date 13 August 2026. ### Neogen Chemicals dividends since 1 April 2021

| Ex-date | Dividend per share | Type |
| --- | --- | --- |
| 13 Aug 2026 | ₹1 | Dividend |
| 19 Sep 2025 | ₹1 | Dividend |
| 19 Sep 2024 | ₹2 | Dividend |
| 25 Aug 2023 | ₹3 | Dividend |
| 19 Sep 2022 | ₹2.75 | Dividend |
| 16 Sep 2021 | ₹2.25 | Dividend |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. The record date is the same day as the ex-date for every payment here. 5 of 5 Of the last 5 financial years, years with an NSE dividend record

Yes. Neogen Chemicals Ltd paid out 18% of its profit as dividends in FY26, and it paid a dividend in 12 of its last 13 reported years. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Neogen Chemicals management say on the latest results call? On the call for April to June 2026, held on 28 September 2026, Neogen Chemicals' management guided: Base-company revenue ₹1,050 crore this year. > “I would say that only some purchase orders for the current quarter, and perhaps some for the next quarter, for electrolyte salt or similar products are legally binding take-or-pay-type contracts. The rest of the revenue projection is based on the assumptions I explained earlier. - Dr. Harin Kanani”
> Managing Director, on the call for April to June 2026

### What management guided

- Battery revenue approximately ₹300 crore this year and above ₹1,000 crore next year. - FY29 battery revenue ₹2,500-3,000 crore and consolidated revenue ₹3,500-4,000 crore. - Nearly ₹1,800 crore of battery capital spending to complete by year-end, covering Dahej capacity up to 2,500 tons of salt/additives and Pakhajan capacity of 30,000 tons of electrolyte plus 3,000 tons of salt; full utilization within two years. - No take-or-pay contracts for most volumes; international salt customers indicated at least 40% purchase, which management linked to 70-80% salt-capacity utilization and ₹700-800 crore revenue. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/9304-28-Sep-2026.pdf). (From the call for April to June 2026, 28 September 2026. The July to September 2026 results are out since, so this part may be out of date until we update it.)

## What to watch in Neogen Chemicals' next results? When Neogen Chemicals reports October to December 2026, these are the 4 checks that show whether the story is still on course. First: Pakhajan commissioning and the remaining US electrolyte approval - check recipe validation and customer qualification progress. - What to check (from the call)
- Pakhajan commissioning and the remaining US electrolyte approval - check recipe validation and customer qualification progress. - Domestic cell plants moving from installation to stable production - check electrolyte offtake conversion and utilization. - QIP deployment toward long-term debt - check debt balance, finance cost and working-capital borrowing. - Salt export indications becoming binding orders - check volume coverage and contract quality. ## Which stock lists is Neogen Chemicals on? Neogen Chemicals is not on any of our India lists this week. ## Is Neogen Chemicals profitable? Neogen Chemicals Ltd earned ₹8.2 Cr of net profit in the Sep 2026 quarter, +144.2% on the same quarter a year earlier. That is the 3rd quarter in a row of profit growth. Full-year FY26 profit was ₹29.0 Cr. Over 10 years profit has grown 19.2% a year on average. That is 2.8% of the quarter's revenue. The same quarter a year earlier earned ₹3.4 Cr. For the full year, FY26 profit was ₹29.0 Cr (−17.1% on the year before). Why profit moved: revenue changed +41.8% on a year earlier and the margin moved +1.0 percentage points. Sales did the work, and the margin was about flat. On average over the last four quarters, profit changed +130.1% and revenue +26.6%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit. ## How much revenue does Neogen Chemicals make, and is it growing? Neogen Chemicals Ltd reported ₹296 Cr of revenue in the Sep 2026 quarter, +41.8% on the same quarter a year earlier. That is the 10th quarter in a row with growth on the year before. Over 10 years it has grown 24.0% a year on average. The last full year, FY26, came in at ₹862 Cr. The last four reported quarters add to ₹1,013 Cr. FY26 revenue was ₹862 Cr, +10.8% on the year before. Recent pace: the last four quarters grew +26.6% on average, against 24.0% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +26.7%, against +17.2% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +55.2%, against +0.0% a year (accelerating). ## How much of every ₹100 of sales does Neogen Chemicals keep? Neogen Chemicals Ltd's operating margin was 15.3% in the Sep 2026 quarter, 1.0 percentage points higher than the same quarter a year ago. Across 13 years it has been between 14.0% and 19.0%. The latest quarter is within that range. Why the margin moved: operating margin changed +1.0 percentage points on the year while gross margin changed −1.8 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Neogen Chemicals' profit turning into cash? Over the last 3 years Neogen Chemicals Ltd's operations used more cash than they brought in, so cash conversion was −64%, a gap worth watching. In FY26 its operations used ₹231 Cr of cash, against ₹29.0 Cr of profit. After ₹800 Cr of spending on assets, free cash was −₹1,031 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why −64% of profit came in as cash: the cash cycle got 86 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 86 days longer. The next section looks at where the cash is stuck. ## Where does Neogen Chemicals' cash go? Neogen Chemicals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 260 days in FY26, up from 174 days in FY21. It spent ₹1,028 Cr on assets over the last 3 years. Customers take 161 days to pay, and stock sits for 445 days on average. At FY26 sales of ₹862 Cr, each day of that cycle ties up about ₹2.4 Cr, so roughly ₹614 Cr is tied up in the business at any time. FY26: customers took 161 days to pay and stock sat for 445 days, about 14.6 months of sales sitting as stock, for a full cycle of 260 days, longer than FY21's 174. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 445 days. Customers pay about 161 days after that. Suppliers are paid at 346 days. Together that makes the 260-day cycle. Spending on assets: ₹1,028 Cr over the last 3 years, against ₹79.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹857 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Neogen Chemicals' P/E ratio, and how does it compare with its own history? Neogen Chemicals Ltd's P/E is 161.7×, near the high end of its own history: higher than 92% of past readings. Its usual P/E (the middle reading) is 82.9×, over 7.5 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Sep 2026 add up to ₹14.71. Why the multiple is where it is: over the past year earnings per share moved −17.4% while the price moved +51.1%. The price did better than earnings, which pushed the multiple up within its own range. Where the price move came from: over 5 years the price moved +11.6% a year; about −3.3% a year came from earnings growth and about +14.9 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Neogen Chemicals business getting better or worse? Neogen Chemicals Ltd's business is getting better. EPS growth hit its low 3 quarters ago at −35.6% and has recovered to +49.0%, with ROCE steady at 9.8%. This is based on 12 quarters of 4 measures. Why it matters: a lasting rise from a low is what this page is built to show. ## How much does Neogen Chemicals earn on its capital? Neogen Chemicals Ltd earned a ROCE of 6% in FY26. Its return on capital used (ROIC) is 8.0 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 3.4% net margin and 0.30× asset turnover (sales divided by assets). Why the return is what it is (FY26): a 3.4% net margin × 0.30× asset turnover × 3.56× leverage (assets divided by equity) ≈ 3.6% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 4.0% − 12.0% = −8.0 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Neogen Chemicals have too much debt? Neogen Chemicals Ltd has total debt of ₹1,395 Cr against shareholder equity of ₹816 Cr as of Jun 2026, so its debt is 1.71× its equity. Year by year, that ratio went from 0.52 in FY22 to 1.71 in FY26. Keep that borrowing in mind when reading the returns on this page. ## What is the Neogen Chemicals shareholding pattern? Foreign institutions cut their stake in Neogen Chemicals Ltd by 3.6 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 4.1% of the company. Promoters moved −2.9 points over the same period, to 48.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: −3.6 points over 8 quarters, to 4.1%; Promoters: −2.9 points over 8 quarters, to 48.3%; Domestic institutions: +1.0 points over 8 quarters, to 23.5%. Why the owners changed: foreign institutions drove it (−3.6 points), together with promoters (−2.9 points). They reduced their stake. ## How far is Neogen Chemicals from balance-sheet trouble? For Neogen Chemicals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Neogen Chemicals rank in its industry? 51.5 out of 100, rank 16 of 30 in Speciality Chemicals, with 90% of the evidence available. Neogen Chemicals Ltd scores 51.5 out of 100 against the 30 companies it is compared with in Speciality Chemicals, ranking 16. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. The four parts add up to the total exactly: 21.8 + 6.3 + 5.5 + 17.9 = 51.5. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Neogen Chemicals compared with? Neogen Chemicals ranks 16 of 30 Speciality Chemicals companies on the 4-Factor Sector Score, with 51.5 out of 100. 1. [Panama Petrochem Ltd](https://www.sectoralpha.in/stocks/panama-petrochem-ltd) PANAMAPET · turning · Sector-leading setup · 96% evidence 80.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.8/35 · Revenue 45.9% · Profit 100% · Operating margin change 14 points · 88% evidence Capital efficiency 15.9/25 · ROCE 19.2% · Operating margin 22% · 100% evidence Valuation 19.7/20 · P/E 5.7× · PEG 0.18 · 100% evidence Relative strength 13.9/20 · Lead over its industry 16.3% · Lead over NIFTY 500 31.3% · 1 year 68.1% · 100% evidence · 10 of 12 weeks ahead Exact sum: 30.8 + 15.9 + 19.7 + 13.9 = 80.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Yasho Industries Ltd](https://www.sectoralpha.in/stocks/yasho-industries-ltd) YASHO · losing its lead · Most evidence points up · 78% evidence 67.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.0/35 · Revenue 54.2% · Profit 100% · Operating margin change 3 points · 100% evidence Capital efficiency 12.3/25 · ROCE 8.9% · Operating margin 21% · 100% evidence Valuation 12.7/20 · P/E 45× · PEG 1.02 · 65% evidence Relative strength 12.2/20 · Lead over its industry n/a · Lead over NIFTY 500 41.1% · 1 year 103.4% · 25% evidence · 11 of 12 weeks ahead Exact sum: 30 + 12.3 + 12.7 + 12.2 = 67.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Vikram Thermo (India) Ltd](https://www.sectoralpha.in/stocks/vikram-thermo-indialtd) breaking out · Evidence leans up · 68% evidence 64.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 16.9% · Profit 41.9% · Operating margin change 8 points · 83% evidence Capital efficiency 21.3/25 · ROCE 36.2% · Operating margin 48% · 95% evidence Valuation 6.6/20 · P/E 25.8× · PEG n/a · 50% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 74.5% · 1 year n/a · 25% evidence · 12 of 12 weeks ahead Exact sum: 23.8 + 21.3 + 6.6 + 12.5 = 64.2 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 4. [Sunshield Chemicals Ltd](https://www.sectoralpha.in/stocks/sunshield-chemicals-ltd) SUNSHIEL · quiet · Evidence leans up · 81% evidence 64.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 12.9% · Profit 100% · Operating margin change 5 points · 88% evidence Capital efficiency 18.8/25 · ROCE 19.9% · Operating margin 16% · 100% evidence Valuation 10.8/20 · P/E 24.3× · PEG 2.21 · 100% evidence Relative strength 10.8/20 · Lead over its industry n/a · Lead over NIFTY 500 4.3% · 1 year -4% · 25% evidence · 0 of 5 weeks ahead Exact sum: 23.6 + 18.8 + 10.8 + 10.8 = 64 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Black Rose Industries Ltd](https://www.sectoralpha.in/stocks/black-rose-industries-ltd) BLACKROSE · quiet · Evidence leans up · 81% evidence 60.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.6/35 · Revenue 8.6% · Profit 28.6% · Operating margin change 6 points · 88% evidence Capital efficiency 16.4/25 · ROCE 18.7% · Operating margin 16% · 100% evidence Valuation 10.0/20 · P/E 17.1× · PEG 4.96 · 100% evidence Relative strength 10.9/20 · Lead over its industry n/a · Lead over NIFTY 500 4.4% · 1 year n/a · 25% evidence · 7 of 12 weeks ahead Exact sum: 23.6 + 16.4 + 10 + 10.9 = 60.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Tatva Chintan Pharma Chem Ltd](https://www.sectoralpha.in/stocks/tatva-chintan-pharma-chem-ltd) TATVA · losing its lead · Evidence leans up · 93% evidence 60.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 49.2% · Profit 100% · Operating margin change 1 points · 100% evidence Capital efficiency 8.7/25 · ROCE 7.2% · Operating margin 19% · 100% evidence Valuation 11.3/20 · P/E 60.2× · PEG 1.21 · 65% evidence Relative strength 11.4/20 · Lead over its industry 7.8% · Lead over NIFTY 500 23.3% · 1 year 15.6% · 100% evidence · 10 of 12 weeks ahead Exact sum: 28.7 + 8.7 + 11.3 + 11.4 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Aether Industries Ltd](https://www.sectoralpha.in/stocks/aether-industries-ltd) AETHER · leader · Evidence leans up · 90% evidence 59.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.4/35 · Revenue 30.2% · Profit 28.4% · Operating margin change 1 points · 100% evidence Capital efficiency 12.8/25 · ROCE 11.9% · Operating margin 32% · 100% evidence Valuation 9.7/20 · P/E 85.1× · PEG n/a · 50% evidence Relative strength 14.8/20 · Lead over its industry 22.3% · Lead over NIFTY 500 38.6% · 1 year 114.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.4 + 12.8 + 9.7 + 14.8 = 59.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [Privi Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/privi-speciality-chemicals-ltd) PRIVISCL · quiet · Evidence leans up · 82% evidence 59.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.7/35 · Revenue 17.5% · Profit 44.5% · Operating margin change -1 points · 95% evidence Capital efficiency 18.5/25 · ROCE 22.3% · Operating margin 26% · 76% evidence Valuation 10.1/20 · P/E 33.7× · PEG n/a · 50% evidence Relative strength 7.1/20 · Lead over its industry -9.7% · Lead over NIFTY 500 4.2% · 1 year 10.5% · 100% evidence · 2 of 12 weeks ahead Exact sum: 23.7 + 18.5 + 10.1 + 7.1 = 59.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Fineotex Chemical Ltd](https://www.sectoralpha.in/stocks/fineotex-chemical-ltd) FCL · leader · Evidence leans up · 96% evidence 59.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.3/35 · Revenue 91.5% · Profit 41% · Operating margin change -2 points · 88% evidence Capital efficiency 13.5/25 · ROCE 18.3% · Operating margin 16% · 100% evidence Valuation 5.7/20 · P/E 46.1× · PEG 1.92 · 100% evidence Relative strength 19.5/20 · Lead over its industry 34.1% · Lead over NIFTY 500 48.9% · 1 year 62.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.3 + 13.5 + 5.7 + 19.5 = 59 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [DMCC Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/dmcc-speciality-chemicals-ltd) DMCC · quiet · Evidence leans up · 93% evidence 55.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.9/35 · Revenue 72.1% · Profit 34.5% · Operating margin change -6.9 points · 100% evidence Capital efficiency 8.7/25 · ROCE 14.8% · Operating margin 4.2% · 100% evidence Valuation 16.1/20 · P/E 16.9× · PEG 0.44 · 65% evidence Relative strength 7.8/20 · Lead over its industry -12.3% · Lead over NIFTY 500 0.9% · 1 year -15.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 22.9 + 8.7 + 16.1 + 7.8 = 55.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Aarti Industries Ltd](https://www.sectoralpha.in/stocks/aarti-industries-ltd) AARTIIND · quiet · Evidence leans up · 100% evidence 55.2 out of 100 Growth Capital Valuation Relative
12. [Galaxy Surfactants Ltd](https://www.sectoralpha.in/stocks/galaxy-surfactants-ltd) GALAXYSURF · leader · Evidence leans up · 81% evidence 53.9 out of 100 Growth Capital Valuation Relative
13. [Pidilite Industries Ltd](https://www.sectoralpha.in/stocks/pidilite-industries-ltd) PIDILITIND · quiet · Evidence leans up · 100% evidence 53.0 out of 100 Growth Capital Valuation Relative
14. [DIC India Ltd](https://www.sectoralpha.in/stocks/dic-india-ltd) DICIND · breaking out · Evidence leans up · 81% evidence 53.0 out of 100 Growth Capital Valuation Relative
15. [Kronox Lab Sciences Ltd](https://www.sectoralpha.in/stocks/kronox-lab-sciences-ltd) KRONOX · breaking out · Evidence leans up · 74% evidence 51.8 out of 100 Growth Capital Valuation Relative
16. Neogen Chemicals Ltd this page NEOGEN · leader · Evidence leans up · 90% evidence 51.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.8/35 · Revenue 26.7% · Profit 55.2% · Operating margin change 0.9 points · 100% evidence Capital efficiency 6.3/25 · ROCE 6.5% · Operating margin 15.3% · 100% evidence Valuation 5.5/20 · P/E 161× · PEG n/a · 50% evidence Relative strength 17.9/20 · Lead over its industry 19% · Lead over NIFTY 500 34.1% · 1 year 50.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.8 + 6.3 + 5.5 + 17.9 = 51.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 17. [Chemcon Speciality Chemicals Ltd](https://www.sectoralpha.in/stocks/chemcon-speciality-chemicals-ltd) CHEMCON · breaking out · Evidence leans up · 85% evidence 51.1 out of 100 Growth Capital Valuation Relative
18. [Alkyl Amines Chemicals Ltd](https://www.sectoralpha.in/stocks/alkyl-amines-chemicals-ltd) ALKYLAMINE · quiet · Evidence leans down · 96% evidence 47.9 out of 100 Growth Capital Valuation Relative
19. [Grauer & Weil (India) Ltd](https://www.sectoralpha.in/stocks/grauer-weil-indialtd) GRAUWEIL · breaking out · Evidence leans down · 96% evidence 46.3 out of 100 Growth Capital Valuation Relative
20. [Paushak Ltd](https://www.sectoralpha.in/stocks/paushak-ltd) PAUSHAKLTD · losing its lead · Evidence leans down · 85% evidence 45.8 out of 100 Growth Capital Valuation Relative
21. [Innovassynth Technologies (India) Ltd](https://www.sectoralpha.in/stocks/innovassynth-technologies-indialtd) breaking out · Too little evidence to rank firmly · 53% evidence 44.0 out of 100 Growth Capital Valuation Relative
22. [Anupam Rasayan India Ltd](https://www.sectoralpha.in/stocks/anupam-rasayan-india-ltd) ANURAS · turning · Evidence leans down · 78% evidence 43.7 out of 100 Growth Capital Valuation Relative
23. [Platinum Industries Ltd](https://www.sectoralpha.in/stocks/platinum-industries-ltd) PLATIND · turning · Evidence leans down · 81% evidence 42.5 out of 100 Growth Capital Valuation Relative
24. [Vinati Organics Ltd](https://www.sectoralpha.in/stocks/vinati-organics-ltd) VINATIORGA · quiet · Evidence leans down · 82% evidence 42.4 out of 100 Growth Capital Valuation Relative
25. [Amal Ltd](https://www.sectoralpha.in/stocks/amal-ltd) AMAL · quiet · Evidence leans down · 68% evidence 41.5 out of 100 Growth Capital Valuation Relative
26. [Amines & Plasticizers Ltd](https://www.sectoralpha.in/stocks/amines-plasticizers-ltd) AMNPLST · quiet · Evidence leans down · 81% evidence 41.1 out of 100 Growth Capital Valuation Relative
27. [Transpek Industry Ltd](https://www.sectoralpha.in/stocks/transpek-industry-ltd) TRANSPEK · losing its lead · Evidence leans down · 63% evidence 38.6 out of 100 Growth Capital Valuation Relative
28. [Vishnu Chemicals Ltd](https://www.sectoralpha.in/stocks/vishnu-chemicals-ltd) VISHNU · losing its lead · Evidence leans down · 100% evidence 38.4 out of 100 Growth Capital Valuation Relative
29. [Clean Science & Technology Ltd](https://www.sectoralpha.in/stocks/clean-science-technology-ltd) CLEAN · breaking out · Evidence leans down · 85% evidence 38.1 out of 100 Growth Capital Valuation Relative
30. [Thirumalai Chemicals Ltd](https://www.sectoralpha.in/stocks/thirumalai-chemicals-ltd) TIRUMALCHM · quiet · Most evidence points down · 68% evidence 27.2 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Speciality Chemicals](https://www.sectoralpha.in/sectors/speciality-chemicals), all 30 compared on one page. ## Which companies are close to Neogen Chemicals in size? Neogen Chemicals is the 10th largest of 30 Speciality Chemicals companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Alkyl Amines Chemicals, Clean Science & Technology and Galaxy Surfactants. Just below it: Fineotex Chemical, Yasho Industries and Tatva Chintan Pharma Chem. ### Speciality Chemicals companies close in size

1. [Alkyl Amines Chemicals Ltd](https://www.sectoralpha.in/stocks/alkyl-amines-chemicals-ltd) ₹8,132 crore
2. [Clean Science & Technology Ltd](https://www.sectoralpha.in/stocks/clean-science-technology-ltd) ₹7,606 crore
3. [Galaxy Surfactants Ltd](https://www.sectoralpha.in/stocks/galaxy-surfactants-ltd) ₹7,502 crore
4. Neogen Chemicals Ltd ₹6,523 crore
5. [Fineotex Chemical Ltd](https://www.sectoralpha.in/stocks/fineotex-chemical-ltd) ₹5,635 crore
6. [Yasho Industries Ltd](https://www.sectoralpha.in/stocks/yasho-industries-ltd) ₹3,888 crore
7. [Tatva Chintan Pharma Chem Ltd](https://www.sectoralpha.in/stocks/tatva-chintan-pharma-chem-ltd) ₹3,845 crore

[All 30 Speciality Chemicals companies, largest first](https://www.sectoralpha.in/sectors/speciality-chemicals#all-companies)

### Companies close in size in other industries

1. [Mahindra Lifespace Developers Ltd](https://www.sectoralpha.in/stocks/mahindra-lifespace-developers-ltd) ₹6,545 crore · Construction & Contracting
2. [Rain Industries Ltd](https://www.sectoralpha.in/stocks/rain-industries-ltd) ₹6,530 crore · Cement
3. Neogen Chemicals Ltd ₹6,523 crore
4. [Hindustan Foods Ltd](https://www.sectoralpha.in/stocks/hindustan-foods-ltd) ₹6,522 crore · FMCG - Contract Mfg
5. [Suprajit Engineering Ltd](https://www.sectoralpha.in/stocks/suprajit-engineering-ltd) ₹6,502 crore · Auto Ancillaries - Diversified

## What else do people ask about Neogen Chemicals? ### What is Neogen Chemicals's share price today? Neogen Chemicals Ltd's share price is ₹2,180.00, +51.1% over the past year. The whole company is worth ₹6,550 Cr on the market. In the last 52 weeks it traded between ₹1,055 to ₹2,488; today it is 78% of the way up from the low, 11.7% above its 200-day average (as of 3 November 2026). ### What were Neogen Chemicals's latest quarterly results? Neogen Chemicals Ltd reported revenue of ₹296 Cr and net profit of ₹8.2 Cr for the Sep 2026 quarter. Revenue rose 41.8% and profit rose 144.2% compared with a year earlier. Earnings per share were ₹2.74. The operating margin was 15.3%, 1.0 percentage points higher than a year earlier (as of 3 November 2026). ### What is Neogen Chemicals's market cap? Neogen Chemicals Ltd's market capitalisation is ₹6,550 Cr at a share price of ₹2,180.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Neogen Chemicals performing? Neogen Chemicals Ltd's share price has been rising for 26 weeks. In its latest quarter, revenue rose 41.8% and profit rose 144.2% compared with a year earlier. Over the past 13 weeks it has done better than the NIFTY 500, for 14 weeks running (as of 3 November 2026). ### Will Neogen Chemicals's share price go up? This page does not forecast Neogen Chemicals Ltd's share price. What it shows instead: the share price is ₹2,180.00, and it has been rising for 26 weeks. Its P/E of 161.7× is higher than 92% of its own last 8 years (as of 3 November 2026). ### Who owns Neogen Chemicals? Promoters own 48.3% of Neogen Chemicals Ltd, foreign institutions 4.1%, domestic institutions 23.5% and the public 24.1% (latest quarter). The biggest change over the last two years: Foreign institutions cut their stake by 3.6 percentage points over 8 quarters (as of 3 November 2026). ### Where is Neogen Chemicals in its business cycle? Neogen Chemicals Ltd's FY26 operating margin was 16.0%, against a 13-year range of 14.0% to 19.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 15.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Neogen Chemicals story? The main question: profits are rising, but only −64% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Neogen Chemicals a stock worth studying right now? What the numbers show: Neogen Chemicals Ltd's share price has risen faster than its earnings: +51.1% in a year, against −17.4% for earnings per share. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Neogen Chemicals share price forecast for 2026? What management itself guided: Base-company revenue ₹1,050 crore this year. This is research, not advice. We’re not SEBI-registered.